Immune Thrombocytopenic Purpura (ITP) in Children: IAP Guidelines
Written By : Ayesha Sadaf
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-01-19 04:45 GMT | Update On 2023-01-19 07:26 GMT
Earlier ITP was referred to as immune thrombocytopenic purpura; however, according to recent guidelines it is accepted as "immune thrombocytopenia".The Indian Academy of Pediatrics (IAP) has released Standard Treatment Guidelines 2022 for Immune Thrombocytopenic Purpura (ITP) in Children. The lead author for these guidelines on Immune Thrombocytopenic Purpura (ITP) in Children is Dr....
Login or Register to read the full article
Earlier ITP was referred to as immune thrombocytopenic purpura; however, according to recent guidelines it is accepted as "immune thrombocytopenia".
The Indian Academy of Pediatrics (IAP) has released Standard Treatment Guidelines 2022 for Immune Thrombocytopenic Purpura (ITP) in Children. The lead author for these guidelines on Immune Thrombocytopenic Purpura (ITP) in Children is Dr. Nitin Shah along with co-author Dr. Anand Kumar and Dr. Anil Rawat. The guidelines come Under the Auspices of the IAP Action Plan 2022, and the members of the IAP Standard Treatment Guidelines Committee include Chairperson Remesh Kumar R, IAP Coordinator Vineet Saxena, National Coordinators SS Kamath, Vinod H Ratageri, Member Secretaries Krishna Mohan R, Vishnu Mohan PT and Members Santanu Deb, Surender Singh Bisht, Prashant Kariya, Narmada Ashok, Pawan Kalyan.
Following are the major recommendations of guidelines:
Etiopathology:
It is an autoimmune disorder characterized by reduced peripheral blood platelet count due to combination of premature platelet destruction and inadequate platelet production.
Diagnosis:
It is a diagnosis of exclusion with typical history and examination; complete blood count (CBC) showing only isolated thrombocytopenia and no atypical cells. Anemia, if present, is in proportion with external bleeding.
Bone marrow examination is not required for diagnosis if peripheral smear is seen by an experienced pathologist or preferably by a pediatric hematologist.
No need for routine testing of antinuclear antibody (ANA), immunoglobulin levels, or H. pylori.
When to do bone marrow examination?
Bone marrow is required before starting steroids by many pediatric hematologists across the country as a good clinical practice, not strictly adhering to the guidelines from West.
Abnormalities such as fever or bone or joint pain, a family history of low platelets or easy bruising, risk factors for HIV infection, skeletal or soft-tissue morphologic abnormalities, nonpetechial rash, lymphadenopathy or an abnormal hemoglobin level, and white blood cell count or white cell morphology are not typical of ITP and should prompt additional testing, such as bone marrow evaluation.
Treatment:
The goal is to minimize the risk of hemorrhage. Decreasing the long-term side effects of treatment are the goals of therapy. Treatment is guided by the severity of bleeding rather than on the platelet count.
The degree of bleeding is based on the World Health Organization (WHO) grading of bleeding, severe bleeding is WHO grade 3 or 4 and those with life-threatening bleeds or intracranial bleeds.
Adolescent patients are treated as per pediatric treatment guidelines.
First line of pharmacotherapy:
• Short course of steroid: Prednisolone 2–4 mg/kg/day (maximum 120 mg) for a short course of 5–7 days. It is preferred over dexamethasone 0.6 mg/kg/day (maximum 40 mg) × 4 days
• IV immunoglobulins: 1 g/kg/day for 1–2 days
• IV anti-D therapy: 50–75 mg/kg provided patient has direct Coombs test negative, Rh positive, and Hb >10 g/dL.
Nonresponders to first-line therapy:
• TPO-RA agonists preferred over rituximab which is preferred over splenectomy.
• TPO-RA agonists are preferred here because of less side effects and to avoid immunosuppression. However, the cost can be exorbitant.
• In the Indian scenario, the cost and availability of TPO-RAs is prohibitive which makes them unsuitable as a frontline therapy. Rituximab is promising with a median response duration of 12.8 months, relative ease of availability, and tolerable side effects.
• Eltrombopag: 1–6 years—25 mg once daily, > 6 years old—50 mg once daily. It has to be taken in empty stomach, median onset of action is at 2 weeks and need to monitor liver function test (LFTs).
• Romiplostim: 1–10 µg/kg subcutaneous once a week
• Injection rituximab 375 mg/m2 once a week × 4 weeks. Dose as low as 100 mg/m2 also have been found to be useful and cost effective.
Alternative immunosuppressive agents: Dapsone, azathioprine, danazol, mycophenolate mofetil, cyclosporine, cyclophosphamide, anti-CD52 monoclonal antibody, vinca alkaloids, and combination of different agents has been tried but data are sparse, especially in children, and hence the American Society of Hematology (ASH) 2019 categorically mentions that recommendations were not feasible.
Dapsone is an easily available low-cost drug with response rates of around 50%; hemolysis, methemoglobinemia, and sulfa allergy being important side effects and is to be avoided in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals.
Splenectomy: It should be deferred, if possible, to beyond 12 months from disease onset. It may be the last resort in situations where ITP is unresponsive to all other therapy, the child shows intolerance to other drugs and quality of life is impaired. It is generally avoided in a child <5 years of age. All age appropriate immunization including meningococcal vaccine should be completed before splenectomy and penicillin prophylaxis should be continued for at least 5 years post-splenectomy.
Secondary ITP: Treat the underlying cause or stop the offending drug.
Outcomes:
Majority of children (60–75%) have acute ITP that resolves within 2–3 months of diagnosis, regardless of therapy. Approximately, 20% of children go on to have chronic ITP. Fewer than 1% of patients develop an intracranial hemorrhage.
Reference:
- Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kühne T, et al. Immune thrombocytopenia—current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41:1-30.
- Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-207.
- Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829-66.
- Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in children and adults. Platelets. 2015;26:164-7.
- Sahi PK, Chandra J. Immune Thrombocytopenia: American Society of Hematology Guidelines, 2019. Indian Pediatr. 2020;57:854-6.
The guidelines can be accessed on the official site of IAP: https://iapindia.org/standard-treatment-guidelines/
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd